Alpha 1-antitrypsin deficiency: genes and variants
Explore variant evidence for Alpha 1-antitrypsin deficiency across 1 analyzed protein (SERPINA1). Linked ClinVar records include 30 pathogenic or likely pathogenic variants, 22 variants of uncertain significance and 20 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-03. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Alpha 1-antitrypsin deficiency
SERPINA1: Alpha-1-antitrypsin
Its circulating alpha-1-antitrypsin activity protects lung tissue by neutralizing neutrophil elastase and related proteases. Severe deficiency predisposes to early emphysema, while accumulation of misfolded protein in hepatocytes can cause chronic liver disease.
30 ClinVar pathogenic / likely pathogenic and 42 uncertain variants in SERPINA1 have source records linked to Alpha 1-antitrypsin deficiency. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Alpha 1-antitrypsin deficiency
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SERPINA1 P393L | 393 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 P393R | 393 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 P393S | 393 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 R63C | 63 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 L65P | 65 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 M409T | 409 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 D280V | 280 | Pathogenic / likely pathogenic (★★) | |
| SERPINA1 E366G | 366 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 E366Q | 366 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 E366K | 366 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 L12P | 12 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 Q64K | 64 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 A82P | 82 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 G249R | 249 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 E288V | 288 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 P52L | 52 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 D201G | 201 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 R247C | 247 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 H39N | 39 | Pathogenic / likely pathogenic (★) | |
| SERPINA1 S77F | 77 | Pathogenic / likely pathogenic | |
| SERPINA1 F76S | 76 | Pathogenic / likely pathogenic | |
| SERPINA1 G91E | 91 | Pathogenic / likely pathogenic | |
| SERPINA1 H358R | 358 | Pathogenic / likely pathogenic | |
| SERPINA1 M1V | 1 | Pathogenic / likely pathogenic | |
| SERPINA1 G216C | 216 | Pathogenic / likely pathogenic | |
| SERPINA1 F57L | 57 | Pathogenic / likely pathogenic | |
| SERPINA1 I116N | 116 | Pathogenic / likely pathogenic | |
| SERPINA1 G139S | 139 | Pathogenic / likely pathogenic | |
| SERPINA1 T320P | 320 | Pathogenic / likely pathogenic | |
| SERPINA1 M382R | 382 | RCL | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Alpha 1-antitrypsin deficiency
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| SERPINA1 P393T | 393 | Conflicting reports (★) | +7: 3 other pathogenic changes within 3 positions; P393L at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.853 |
Which prediction tools work for Alpha 1-antitrypsin deficiency
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 88 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 86 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 83 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 83 out of 100
- CADD: 81 out of 100
- SIFT: 81 out of 100
- VARITY: 80 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 78 out of 100
- MetaLR: 78 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 77 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 74 out of 100
- ESM1b (LLR): 74 out of 100
- phastCons: 73 out of 100
- SpliceAI: 56 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 54 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Alpha 1-antitrypsin deficiency
- Carpal tunnel syndrome, also linked to SERPINA1
Frequently asked questions
Which genes have records linked to Alpha 1-antitrypsin deficiency?
This view contains 1 analyzed proteins: SERPINA1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 30 pathogenic or likely pathogenic variants, 22 variants of uncertain significance and 20 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 129 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center